Loading company…
Montreal-based biopharmaceutical company developing REP 2139 for chronic hepatitis B and hepatitis delta infections.
Replicor Inc. was founded in 2013 and is headquartered in Montreal, Canada. Its main product is REP 2139, a nucleic acid polymer in clinical evaluation for hepatitis B (HBV) and hepatitis delta (HDV) infections, including four proof-of-concept Phase II trials. Michel Bazinet is CEO. The company's only funding deal was in 2015, when Venrock invested an undisclosed amount. Stage: Seed.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in